New combo shows promise for High-Risk leukemia patients
NCT ID NCT02688140
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new treatment for adults with a high-risk form of acute promyelocytic leukemia (APL). The experimental therapy combined arsenic trioxide, ATRA, and a low dose of idarubicin, aiming to improve survival and reduce side effects compared to the standard chemotherapy regimen. The trial enrolled 133 patients across Europe to see if this approach leads to better outcomes and quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE PROMYELOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AML-CG study group
All Participating Sites, Germany
-
AML-SG study group
All Participating Sites, Germany
-
French-Belgian-Swiss APL study group
All Participating Sites, France
-
GIMEMA study group
All Participating Sites, Italy
-
HOVON study group
All Participating Sites, Netherlands
-
OSHO study group
All Participating Sites, Germany
-
PETHEMA study group
All Participating Sites, Spain
-
SAL study group
All Participating Sites, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.